Histology-Agnostic

Histology-agnostic refers to medical decisions, drug approvals, or treatment approaches that are based on a tumor's molecular or genetic features rather than on the tissue type or organ where the cancer originated. In this approach, what matters is what the cancer is at the DNA or protein level, not where it started or how it looks under the microscope. This is sometimes called "tissue-agnostic" or "tumor-agnostic" care.

Origin

The term emerged in oncology in the mid-2010s after the U.S. FDA began approving cancer drugs based on shared molecular markers across different tumor types. The 2017 approval of pembrolizumab for any solid tumor with high microsatellite instability (MSI-H) is widely considered the first true histology-agnostic approval.

Significance in Asbestos Context

For mesothelioma patients, histology-agnostic thinking is opening doors that did not exist a decade ago. Mesothelioma has historically been treated based on its subtype (epithelioid, sarcomatoid, or biphasic), but newer therapies may be available to a patient whose tumor carries a specific molecular feature, regardless of subtype. Examples include drugs targeting BAP1 loss, NF2 mutations, MTAP/CDKN2A deletion, or high tumor mutational burden, as well as immunotherapies approved across many cancer types. Patients should ask whether their tumor has had molecular or genomic testing (sometimes called next-generation sequencing or NGS), because the results may qualify them for histology-agnostic FDA-approved drugs or clinical trials that would otherwise be overlooked when treatment is chosen by tissue type alone.

Example Sentence

After her epithelioid mesothelioma stopped responding to chemotherapy, her oncologist ordered molecular testing to see whether she qualified for any histology-agnostic therapies or trials.

Related Terms

Tumor Mutational Burden, BAP1, Next-Generation Sequencing, Targeted Therapy, Immunotherapy, Mesothelioma Subtypes

Notes

• Ask your oncologist whether your tumor tissue has been sent for comprehensive molecular or genomic profiling, and request a written copy of the report for your medical records.
• Specifically ask whether your tumor has been tested for MSI-H, dMMR, high TMB, NTRK fusions, RET fusions, or BRAF V600E, as each can qualify patients for histology-agnostic FDA-approved drugs.
• Keep all pathology reports, molecular test results, and tumor block location information; these documents may also be important evidence in a legal claim showing the specific cancer diagnosis.
• If your local oncologist is unfamiliar with histology-agnostic options for mesothelioma, request a second opinion at a mesothelioma specialty center or NCI-designated cancer center.